Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $33.68 Consensus Price Target from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been given an average rating of “Hold” by the thirty research firms that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $33.68.

SRPT has been the topic of a number of analyst reports. Royal Bank Of Canada upped their target price on shares of Sarepta Therapeutics from $14.00 to $16.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 8th. Piper Sandler increased their price objective on Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Guggenheim dropped their target price on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Leerink Partners upped their price target on Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a “market perform” rating in a report on Tuesday, September 9th. Finally, Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $19.00 to $26.00 in a research note on Wednesday, November 5th.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $21.04 on Wednesday. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $129.84. The stock’s 50 day moving average is $20.76 and its 200-day moving average is $20.53. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of -6.99 and a beta of 0.54.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The business had revenue of $399.36 million for the quarter, compared to the consensus estimate of $331.51 million. During the same quarter last year, the firm posted $0.62 EPS. The business’s revenue for the quarter was down 14.5% compared to the same quarter last year. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares in the company, valued at approximately $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently modified their holdings of SRPT. Ancora Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 300 shares in the last quarter. Brooklyn Investment Group boosted its position in Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 590 shares during the last quarter. Public Employees Retirement System of Ohio grew its stake in Sarepta Therapeutics by 2.2% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company’s stock valued at $492,000 after purchasing an additional 607 shares during the period. State of Michigan Retirement System grew its stake in Sarepta Therapeutics by 3.1% in the 2nd quarter. State of Michigan Retirement System now owns 23,600 shares of the biotechnology company’s stock valued at $404,000 after purchasing an additional 700 shares during the period. Finally, Arizona State Retirement System increased its position in shares of Sarepta Therapeutics by 2.8% during the 3rd quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company’s stock valued at $504,000 after purchasing an additional 717 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.